When is Onyx Getting Bought?

Quote
Anonymous said:
What data are we expecting at ASH that the street doesn't know about already? I'd love to wait until after Q4 earnings call to sell, but our capital gains taxes could be 15% higher by then, correct?
Click to expand...

I think, perhaps incorrectly, that the market will be down until April-ish. We will likely bounce around from 72-80, until Q2 earnings and fiscal cliff issues are set motion. Should have sold when we hit 90s, but everyone thought we were going to hit 100 by early Jan. I guess, it never pays to be to greedy. Once congress decides how much our taxes are going up things will improve. Hold until April-July. My two cents...
 
























Soon if you read the story from the street

13 Biotech Stock Predictions for 2013
By Adam Feuerstein01/02/13 - 06:00 AM EST

10. By the end of the year, one or more of these companies will be gobbled up an M&A deal: BioMarin Pharmaceuticals(BMRN_), Onyx Pharmaceuticals(ONXX_), Medivation(MDVN_), Achillion Pharmaceuticals(ACHN_) and Incyte(INCY_).
 






Anonymous said:
Soon if you read the story from the street

13 Biotech Stock Predictions for 2013
By Adam Feuerstein01/02/13 - 06:00 AM EST

10. By the end of the year, one or more of these companies will be gobbled up an M&A deal: BioMarin Pharmaceuticals(BMRN_), Onyx Pharmaceuticals(ONXX_), Medivation(MDVN_), Achillion Pharmaceuticals(ACHN_) and Incyte(INCY_).
Click to expand...

You can literally find the same article each of the last 8 years with regards to Onyx...nothing new.
 






Anonymous said:
You can literally find the same article each of the last 8 years with regards to Onyx...nothing new.
Click to expand...

Yes, but up until this past 6 months Onyx only had 1/2 of a drug now they have 1/2 of 2 drugs and one that they own 100% so they actually have something other companies want now. That was not the case the previous 7 1/2 years.
 






Sales reps should learn how to read...the reason Bayer is not doing a buyout is that they can not afford it. Read the newspaper --- they have over 6000 lawsuits pending for Yaz and have had to set aside 1.5 billion for settlements, they are facing a potential 500Million (yes another half a billion) dollar class action gender lawsuit --- very similar to Novartis --- that they will most likely loose, they had a Crop Science settlement...and the legal list goes on and on. You think your "compensation" is tough now, if Bayer owned you, you would have far less.

Learn how to read...

http://www.foxnews.com/world/2013/0...-40-million-after-birth-control-pill-lawsuit/
 






Anonymous said:
Sales reps should learn how to read...the reason Bayer is not doing a buyout is that they can not afford it. Read the newspaper --- they have over 6000 lawsuits pending for Yaz and have had to set aside 1.5 billion for settlements, they are facing a potential 500Million (yes another half a billion) dollar class action gender lawsuit --- very similar to Novartis --- that they will most likely loose, they had a Crop Science settlement...and the legal list goes on and on. You think your "compensation" is tough now, if Bayer owned you, you would have far less.

Learn how to read...

http://www.foxnews.com/world/2013/0...-40-million-after-birth-control-pill-lawsuit/
Click to expand...

Interesting you’re telling people to learn how read by writing it…how would they know what you are writing if you they don’t know how to read? I know smart is not your thing.

Well on to the point you were trying to make. Thanks for ruling out one of dozens of possible suitors. Cracker Jack job there! Give us your analysis on why BMS won’t take ONXX out…TC has long standing relationships at BMS, they have publically stated that they are in acquisition mode and Biogen with a $41B MC is probably a bit of a red herring. My guess is they grab ONXX for $130 a share = $8.8B versus dropping the mother lode on BIIB @ $59B.
 






Top Bottom
Back
Quote